Patents by Inventor Beatrix Blume

Beatrix Blume has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors
    Patent number: 9688684
    Abstract: The present invention relates to tetrahydro-tetrazolo[1,5-a]pyrazine compounds of formula (I), wherein R1 denotes —R3, —CH2—R3 or —CO—R3; R2 denotes Ar2, Hetar2 or C3-7-cycloalkyl; and R3 denotes Ar3, Hetar3 or C3-7-cycloalkyl. These compounds are useful for inhibiting the retinoid-related orphan receptor ? (ROR ?, ROR-gamma) and for the prevention and/or treatment of medical conditions affected by ROR ? activity such as rheumatoid arthritis, multiple sclerosis, psoriasis, ulcerative colitis, asthma, autoimmune hepatitis or type 1 and type 2 diabetes.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: June 27, 2017
    Assignee: Merck Patent GmbH
    Inventors: Dirk Finsinger, Margarita Wucherer-Plietker, Beatrix Blume
  • TETRAHYDRO-TETRAZOLO[1,5-A]PYRAZINES AS ROR-GAMMA INHIBITORS
    Publication number: 20160311830
    Abstract: The present invention relates to tetrahydro-tetrazolo[1,5-a]pyrazine compounds of formula (I), wherein R1 denotes —R3, —CH2—R3 or —CO—R3; R2 denotes Ar2, Hetar2 or C3-7-cycloalkyl; and R3 denotes Ar3, Hetar3 or C3-7-cycloalkyl. These compounds are useful for inhibiting the retinoid-related orphan receptor ? (ROR ?, ROR-gamma) and for the prevention and/or treatment of medical conditions affected by ROR ? activity such as rheumatoid arthritis, multiple sclerosis, psoriasis, ulcerative colitis, asthma, autoimmune hepatitis or type 1 and type 2 diabetes.
    Type: Application
    Filed: November 26, 2014
    Publication date: October 27, 2016
    Applicant: MERCK PATENT GmbH
    Inventors: Dirk FINSINGER, Margarita WUCHERER-PLIETKER, Beatrix BLUME
  • Novel 2-amino-4-quinazolinones and 2-amino-4-oxoquinazolones as LXR nuclear receptor binding compounds with partial agonistic properties
    Publication number: 20050261319
    Abstract: The present invention relates to compounds according to the general formulas (I) and/or (Ia), which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.
    Type: Application
    Filed: March 9, 2005
    Publication date: November 24, 2005
    Inventors: Ulrich Deuschle, Ralph Loebbert, Beatrix Blume, Manfred Koegl, Claus Kremoser, Ingo Kober, Ulrike Bauer, Kristina Hermann, Michael Albers
  • DNA constructs and plants incorporating them
    Patent number: 6204437
    Abstract: Expression of genes inserted into plants by transformation is controlled by the use of a promoter selected from Aco1, Aco2 and Aco3, the sequences of which are given. The level of expression obtained by use of these promoters varies with the stage of development of the plant.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: March 20, 2001
    Assignee: Zeneca Limited
    Inventors: Donald Grierson, Beatrix Blume, Andrew Hamilton, Michael Holdsworth, Cornelius Barry